18 results about "Inflammatory lung disease" patented technology

IL33 antagonists, alone or in combination with IL-4R antagonists, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in subjects having one or more risk alleles in intronic IL1RL1 variant rs1420101, in IL33 variant rs1342326, in both, or in variants in linkage disequilibrium therewith.

The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or a pharmaceutically acceptable salt thereof in the inhalation treatment of inflammatory lung diseases. The present invention particularly relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for this purpose. Advantageous features of an aerosol containing 5-amino-2,3-dihydro-1,4-phthalazinedione or a pharmaceutically acceptable salt thereof and a method for producing the aerosol are disclosed. The present invention further relates to a kit for the inhalation treatment of inflammatory lung diseases.

This disclosure relates to compounds of formula I (wherein X and R1-R4, n and m have the meanings set forth herein) and pharmaceutically acceptable salts thereof. Compounds of formula I exhibit GPR183 antagonist activity and are therefore useful in the treatment or prevention of disorders, conditions or diseases for which GPR183 antagonists have been shown to be useful, such as chronic pain, e.g., osteoarthritis, chronic low back pain, neuropathic pain, and immune system disorders, e.g., inflammatory bowel diseases such as colitis and Crohn's disease, multiple sclerosis, rheumatoid arthritis, inflammatory lung diseases, e.g., asthma, and psoriasis. TIFF2026522963000085.tif2570

The invention discloses a liposome preparation prepared from a benzoyl guanidine derivative LY104 crystal form as well as a preparation method and application of the liposome preparation, and belongs to the technical field of medicines. The invention provides a liposome for inflammatory lung diseases, which takes LY104 and a novel crystal form thereof as active ingredients. The liposome prepared by the invention is good in stability, stable in membrane drug loading, and suitable for atomization drug delivery, and the particle size can be controlled to be 50-200nm. Meanwhile, the liposome preparation provided by the invention can delay drug release, prolong the onset time, improve the tolerated dose of single administration, reduce drug irritation, and can be used for treating inflammatory lung diseases, after being freeze-dried, the liposome preparation provided by the invention is dispersed in saline water to be atomized and inhaled, so that the bitter taste of the drug can be greatly covered, and the bioavailability of the drug is improved. The lipidosome preparation has the advantages that drug irritation is reduced, drug bioavailability is improved, patient compliance is improved, the lipidosome preparation can optimize the in-vivo metabolic process of the benzoyl guanidine derivative, the curative effect of the benzoyl guanidine derivative on treating inflammatory lung diseases is enhanced, and the application prospect is wide. The liposome preparation provided by the invention can be used for treating inflammatory lung diseases such as asthma, chronic obstructive pulmonary disease and the like in a more targeted manner, and has a wide market application prospect.

The present invention generally relates to the treatment of chronic obstructive pulmonary disease (CORD), and to therapeutic agents useful therefor. In particular, the present invention relates to antibodies, including bispecific antibodies inhibiting IL-33 and IL-6, useful for the treatment of inflammatory lung disease. In addition, the invention relates to polynucleotides encoding such antibodies, vectors and host cells comprising such polynucleotides, as well as methods for producing such antibodies.

The invention discloses application of piperlongumine in treating and preventing lung injury, and belongs to the technical field of medicines. Aiming at the technical bottlenecks of limited treatment means and high case fatality rate of the existing acute lung injury (ALI) / acute respiratory distress syndrome (ARDS), the invention discovers that piperlongumine can specifically inhibit cGAS-STING signal channel activation for the first time, and expression release of inflammatory factors IFN-beta, IL-6 and TNF-alpha is reduced by regulating phosphorylation of a downstream interferon regulatory factor 3 (IRF3). In-vitro experiments prove that piperlongumine inhibits ISD-induced inflammatory response in a dose-dependent manner, and in-vivo experiments show that piperlongumine can significantly relieve LPS-induced mouse acute lung tissue inflammatory cell infiltration, reduce serum IL-6 and TNF-alpha levels, and improve lung tissue pathological injury. According to the invention, the medicinal application of piperlongumine is expanded, a new lung injury treatment scheme based on natural active compounds is provided, and the piperlongumine can be widely applied to prevention and treatment of acute lung injury and related inflammatory lung diseases.

An IL33 antagonist, alone or in combination with an IL-4R antagonist, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyp in a subject having one or more risk alleles in the intron IL1RL1 variant rs1420101, in the IL33 variant rs1342326, both, or in variants of their linkage imbalance.

The invention relates to a recombinant human alpha 1-antitrypsin (rhAAT) glycoprotein or a fragment thereof. In embodiments, the rhAAT or fragment has one or more N-linked glycosylation, including at least one HexNAC1 glycosylation. In other embodiments, the rhAAT glycoprotein or a fragment thereof comprises at least one of the glycosylation of Hex9 HexNac2, Hex10 HexNac2, Hex11 HexNac2, Hex12 HexNac2, Hex13 HexNac2, Hex14 HexNac2, Hex15 HexNac2, and / or Hex16 HexNac2. The invention further relates to the use of the rhAAT glycoprotein or the fragment thereof. The present invention also relates to a protein formulation comprising a recombinant human alpha 1-antitrypsin (rhAAT) glycoprotein or a fragment thereof having a heterologous N-linked glycosylation. In embodiments, the rhAAT protein or a fragment thereof is expressed in Pichia pastoris. The invention also relates to a method for producing the rhAAT of the invention. The invention also relates to a pharmaceutical composition comprising the rhAAT glycoprotein or the fragment thereof or the protein preparation. The present invention also relates to such rhAAT glycoproteins or fragments thereof, protein formulations or pharmaceutical compositions for use in the treatment of various medical conditions, such as the treatment of viral infections, viral respiratory infections, bacterial infections and / or bacterial respiratory infections, other respiratory or vascular diseases and / or for the treatment of inflammatory lung diseases.

The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts in the treatment of rare chronic inflammatory lung diseases. The present invention particularly relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for said purpose.

IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof. 20 24 22 02 14 30 S ep 2 02 4 A B S T R A C T 2 0 2 4 2 2 0 2 1 4 3 0 2 0 2 4 S e p

The invention discloses a dihydrochalcone compound Invoucrasin H as well as a preparation method and application of the dihydrochalcone compound Invoucrasin H. The Invoucrasin H is obtained by being separated from a leguminosae seguinea plant ephedra cochinchinensis. Researches on an in-vivo lipopolysaccharide-induced acute lung injury mouse model and an in-vitro human bronchial epithelial cell inflammation model show that the compound can significantly reduce the levels of inflammatory factors IL-6, IL-1beta and TNF-alpha, and alleviate lung tissue inflammatory response and pathological injury. The invention also provides an application of the Invoucrasin H in preparation of medicines for preventing and treating acute lung injury and related inflammatory lung diseases. The invention provides a new natural small molecule candidate drug for treating acute lung injury.

This disclosure provides pharmaceutical preparations, products, and methods relating to ARINA-1 for use in treating patients with chronic inflammatory lung diseases, such as lung transplant, cystic fibrosis (CF), non-CF bronchiectasis, chronic obstructive pulmonary disease (COPD, and other inflammatory lung diseases.

The invention discloses a medicine containing a small molecule compound with a 2-aryl formyl benzo-aza structure and application of the medicine. The small molecule compound with the 2-arylformyl benzo-aza structure and pharmaceutically acceptable salt or eutectic, deuterated compound, solvate and enantiomer thereof can be used for preparing medicines for preventing and / or treating inflammatory lung diseases, or preparing medicines for inhibiting alveolar macrophages from generating inflammatory factors; the medicine is a medicine which contains a small molecule compound with a 2-aryl formyl benzo-aza structure and is used for preventing and / or treating inflammatory lung diseases. The compound provided by the invention can provide a new treatment strategy for preventing or treating inflammatory lung diseases, and has a wide application prospect.

The application discloses a medicine containing a small-molecule compound with a 2-aromatic benzoyl benzazepine structure and an application thereof. The small-molecule compound with the 2-aromatic benzoyl benzazepine structure and a pharmaceutically acceptable salt or co-crystal, deuterated compound, solvate or enantiomer thereof can be used for preparing a medicine for preventing and / or treating an inflammatory lung disease or for preparing a medicine for inhibiting alveolar macrophages from producing inflammatory factors; the medicine is a medicine for preventing and / or treating an inflammatory lung disease and contains the small-molecule compound with the 2-aromatic benzoyl benzazepine structure. The compound provided by the application can provide a new treatment strategy for the prevention or treatment of an inflammatory lung disease and has a wide application prospect.

IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof.